Clinical trial POLARIX
POLARIX - GO39942 - A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Lysarc |
| EudraCT Identifier | 2017-002023-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03274492 |
| Inclusion criteria | Previously untreated patients with CD20-positive DLBCL - IPI score of 2-5 |
| Last update |